By: Alfonso Miranda Londoño & Juan D. Gutiérrez-Rodríguez
Historically, the airline industry has been characterized by the heavy regulation established by the State. In effect, during the first six decades of the existence of these services in most of the developed countries, the governments applied a strict regulation in all the aspects of the service, a strong policy of subsidies and different entry barriers of legal origin that restricted the competition in the market. However, in the seventies the government of the United States deregulated the market, liberalizing the tariffs and allowing the market to work with more flexibility. Deregulation gave antitrust law and important role in regards to the promotion and preservation of competition in the market.
In Colombia the evolution of the regulation of the airline industry has followed a similar tendency. Since the year 1992 until the issuance of the Resolution 3299 of 2007, the intervention of the Special Administrative Unit of Civil Aeronautics (AEROCIVIL) over the aeronautic tariffs consisted on their approval for each route on a maximum-minimum price basis. The issuance of the Resolution 3299 of 2007 by the AEROCIVIL, that liberated the national and international tariffs of the regular air transport of passengers had an immediate effect of increasing the competition, reflected on the substantial decrease of tariffs and the entrance of new firms.
Taking into account this context, the purpose of the paper is to present in detail the special competition regime in the Colombian aeronautical sector. The document explains the faculties of the as the competition authority of the aeronautics sector and analyzes the commercial policies of airlines and travel agencies.
Full Content: SSRN
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas